Page last updated: 2024-11-07

cholylsarcosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cholylsarcosine: structure given in first source; resistant to deconjugation & dehydroxylation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID168312492
MeSH IDM0171760

Synonyms (1)

Synonym
cholylsarcosine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Cholylsarcosine was shown to be well absorbed from the ileum but underwent little absorption from the jejunum or colon."( Transport, metabolism, and effect of chronic feeding of cholylsarcosine, a conjugated bile acid resistant to deconjugation and dehydroxylation.
Angellotti, MA; Hofmann, AF; Marcus, SN; Rossi, SS; Schmassmann, A; Schteingart, CD; Ton-Nu, HT, 1990
)
0.28

Dosage Studied

ExcerptRelevanceReference
" In this work a microgranule dosage form was developed to protect the gastric mucosa while facilitating rapid generation of CS levels in the duodenum."( Enteric-coated cholylsarcosine microgranules for the treatment of short bowel syndrome.
Bott, C; Dressman, JB; Fürst, T; Stein, J, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (47.62)18.2507
2000's6 (28.57)29.6817
2010's5 (23.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (14.29%)5.53%
Reviews1 (4.76%)6.00%
Case Studies5 (23.81%)4.05%
Observational0 (0.00%)0.25%
Other12 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Hepatic Transport of Conjugated Bile Acids in Humans Quantified by 11C-cholylsarcosine PET/CT [NCT01879735]Phase 122 participants (Actual)Interventional2013-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01879735 (1) [back to overview]Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar

Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar

(NCT01879735)
Timeframe: All measurements are performed in one day.

Interventionpercentage of participants (Number)
ICG Infusion100
Infusion Method100

[back to top]